Atea Pharmaceuticals (AVIR) Operating Income: 2019-2024
Historic Operating Income for Atea Pharmaceuticals (AVIR) over the last 6 years, with Dec 2024 value amounting to -$192.9 million.
- Atea Pharmaceuticals' Operating Income fell 132.93% to -$39.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$130.7 million, marking a year-over-year decrease of 194.42%. This contributed to the annual value of -$192.9 million for FY2024, which is 17.54% down from last year.
- Per Atea Pharmaceuticals' latest filing, its Operating Income stood at -$192.9 million for FY2024, which was down 17.54% from -$164.2 million recorded in FY2023.
- Atea Pharmaceuticals' 5-year Operating Income high stood at $138.4 million for FY2021, and its period low was -$192.9 million during FY2024.
- Moreover, its 3-year median value for Operating Income was -$164.2 million (2023), whereas its average is -$162.6 million.
- Its Operating Income has fluctuated over the past 5 years, first surged by 1,354.55% in 2021, then plummeted by 194.42% in 2022.
- Atea Pharmaceuticals' Operating Income (Yearly) stood at -$11.0 million in 2020, then skyrocketed by 1,354.55% to $138.4 million in 2021, then tumbled by 194.42% to -$130.7 million in 2022, then decreased by 25.65% to -$164.2 million in 2023, then dropped by 17.54% to -$192.9 million in 2024.